Dr. Jonathan D. Tward had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma
Article first published online: 17 MAY 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 1, pages 108–115, 1 July 2006
How to Cite
Tward, J. D., Wendland, M. M. M., Shrieve, D. C., Szabo, A. and Gaffney, D. K. (2006), The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107: 108–115. doi: 10.1002/cncr.21971
- Issue published online: 16 JUN 2006
- Article first published online: 17 MAY 2006
- Manuscript Accepted: 28 FEB 2006
- Manuscript Revised: 16 FEB 2006
- Manuscript Received: 11 JAN 2006
- 1American Cancer Society. Cancer Facts and Figures, 2005. Atlanta: American Cancer Society; 2005.
- 5Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985; 103: 195–200., , , et al.
- 10Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004; 22: 4926–4933., , , et al.
- 14National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat, ver 5.3.1. [computer program]. Bethesda: National Cancer Institute.
- 23RiesLAG, EisnerM, KosaryCL, et al., editors. SEER Cancer Statistics Review, 1975-2002. Bethesda: National Cancer Institute; 2005.
- 36National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER data quality. Available at URL: http://seer.cancer.gov/about/quality.html Accessed May 6, 2005.
- 37National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (available at URL: www.seer.cancer.gov). SEER*Stat data base: incidence-SEER 13 registries, public use, 1973-2002 varying (based on the November 2004 submission; released April 2005). Bethesda: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2005.